#62025TO0844EU court order on EMA publication of Dazluma withdrawal report
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order deals with whether the European Medicines Agency can publish its public assessment report after Biohaven withdrew its marketing authorisation application for Dazluma, an orphan medicine candidate for a rare neurological disorder. The case matters for drug developers because it tests how much control a company has over EMA documents once an EU authorisation review is under way. Companies withdrawing applications should expect that EMA transparency rules may still lead to publication, unless they can show a strong and urgent reason to stop it.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Reviews Biohaven’s request to stop EMA from publishing the Dazluma withdrawal assessment report
- Highlights EMA transparency risks after a company withdraws a marketing authorisation application
- Signals that companies need strong, urgent evidence to block publication of EMA assessment material
Obligations
What this law requires
This judicial order concerns EMA's decision of 27 October 2025 to publish a withdrawal European public assessment report for Dazluma after the marketing authorisation application was withdrawn; it does not itself impose a new direct compliance obligation on drug developers.
Marketing authorisation applicants for centrally authorised medicinal products should expect EMA transparency rules under Regulation (EC) No 726/2004 to permit publication of assessment materials, including a withdrawal EPAR, unless interim relief suspending publication is granted.
A party seeking to prevent publication of an EMA withdrawal EPAR through interim relief must demonstrate a prima facie case, urgency, and that the weighing of interests supports suspension of operation of the EMA decision.